{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "vascular:thrombophilia:heparin-induced:definition",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T18:08:00.000Z",
    "contributors": [
      "copilot"
    ],
    "status": "enhanced",
    "confidence": 0.95,
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/thrombophilia",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "critical",
    "board_yield": "HIGH"
  },
  "content": {
    "term": "Heparin-Induced Thrombocytopenia",
    "synonyms": [
      "HIT",
      "HIT Type II",
      "Heparin-Induced Thrombocytopenia and Thrombosis (HITT)"
    ],
    "definition": "An immune-mediated prothrombotic disorder caused by platelet-activating antibodies against platelet factor 4 (PF4) complexed with heparin. Despite causing thrombocytopenia, HIT paradoxically increases thrombosis risk, making it a critical diagnosis in hospitalized patients on heparin.",
    "classification": {
      "type_I": {
        "mechanism": "Non-immune, direct heparin effect",
        "timing": "Days 1-4",
        "platelet_drop": "Mild, transient",
        "thrombosis_risk": "None",
        "management": "Continue heparin - benign"
      },
      "type_II": {
        "mechanism": "Immune-mediated (anti-PF4/heparin antibodies)",
        "timing": "Days 5-14 (or earlier if prior exposure)",
        "platelet_drop": ">50% from baseline or <100,000",
        "thrombosis_risk": "Very high (30-50%)",
        "management": "STOP heparin, start alternative anticoagulation"
      }
    },
    "pathophysiology": {
      "mechanism": [
        "Heparin binds to platelet factor 4 (PF4) on platelets",
        "PF4/heparin complex becomes immunogenic",
        "IgG antibodies form against complex",
        "Antibodies activate platelets \u2192 thrombocytopenia",
        "Activated platelets release procoagulant microparticles",
        "Intense thrombin generation \u2192 thrombosis"
      ]
    },
    "clinical_features": {
      "thrombocytopenia": [
        ">50% fall from baseline (most important)",
        "Nadir typically 50,000-80,000 (rarely <20,000)",
        "Severe thrombocytopenia suggests other diagnosis"
      ],
      "timing": [
        "Typical onset: day 5-14 of heparin",
        "Rapid onset if heparin exposure in past 100 days"
      ],
      "thrombosis": [
        "Venous > arterial (4:1 ratio)",
        "DVT/PE most common",
        "Arterial: stroke, MI, limb ischemia",
        "Adrenal hemorrhage (venous infarction)"
      ],
      "skin_manifestations": [
        "Skin necrosis at injection sites",
        "May precede thrombocytopenia"
      ]
    },
    "diagnosis": {
      "4ts_score": {
        "components": [
          "Thrombocytopenia severity",
          "Timing of platelet fall",
          "Thrombosis present",
          "oTher causes excluded"
        ],
        "interpretation": [
          "0-3: Low probability - HIT unlikely",
          "4-5: Intermediate - test and treat",
          "6-8: High probability - treat immediately"
        ]
      },
      "laboratory": {
        "screening": "PF4/heparin ELISA (high sensitivity, moderate specificity)",
        "confirmatory": "Serotonin release assay (SRA) - gold standard",
        "approach": "Use 4Ts \u2192 if intermediate/high \u2192 ELISA \u2192 if positive \u2192 SRA"
      }
    },
    "management": {
      "stop_heparin": "ALL heparin including flushes, coated catheters",
      "alternative_anticoagulation": [
        "Argatroban (hepatic metabolism) - most common in US",
        "Bivalirudin (for PCI or short-term)",
        "Fondaparinux (off-label but commonly used)",
        "DOACs (after acute phase, platelet recovery)"
      ],
      "avoid_warfarin": [
        "DO NOT start until platelets >150,000",
        "Warfarin depletes protein C \u2192 venous limb gangrene",
        "Overlap with non-heparin anticoagulant first"
      ],
      "platelet_transfusion": "Avoid unless life-threatening bleeding"
    },
    "outcomes": {
      "thrombosis_rate": "30-50% if untreated",
      "mortality": "10-20%",
      "limb_loss": "10-15%",
      "with_early_treatment": "Outcomes markedly improved"
    },
    "statement": "vascular:thrombophilia:heparin-induced:definition is a fundamental concept in Health-Sciences Medicine Surgery Vascular Thrombophilia that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding vascular:thrombophilia:heparin-induced:definition helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of vascular:thrombophilia:heparin-induced:definition include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of vascular:thrombophilia:heparin-induced:definition."
    }
  },
  "codes": {
    "snomed_ct": "73310007",
    "icd_10": "D75.82"
  },
  "relationships": {
    "broader": [
      "vascular:thrombophilia:acquired"
    ],
    "related": [
      "vascular:anticoagulation:complications",
      "vascular:dvt:treatment"
    ],
    "narrower": []
  },
  "pedagogical": {
    "learning_objectives": [
      "Recognize clinical features and timing of HIT",
      "Use the 4Ts score for pretest probability",
      "Know management: stop heparin, start non-heparin anticoagulant"
    ],
    "clinical_pearls": [
      "HIT is a PROTHROMBOTIC disorder despite low platelets - DO NOT transfuse",
      "Day 5-14 timing is classic; earlier if prior heparin in 100 days",
      ">50% platelet drop more important than absolute count",
      "DO NOT start warfarin until platelets >150K (risk of venous limb gangrene)",
      "4Ts score: low score rules out HIT; high score = treat empirically",
      "Argatroban in US; bivalirudin for PCI; fondaparinux off-label but effective"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). vascular:thrombophilia:heparin-induced:definition. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}